Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Viking Therapeutics (VKTX) Operating Expenses (2016 - 2026)

Viking Therapeutics (VKTX) has disclosed Operating Expenses for 13 consecutive years, with $164.1 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Expenses rose 195.89% year-over-year to $164.1 million; the TTM value through Mar 2026 reached $502.0 million, up 191.32%, while the annual FY2025 figure was $393.3 million, 160.63% up from the prior year.
  • Operating Expenses hit $164.1 million in Q1 2026 for Viking Therapeutics, roughly flat from $164.7 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $164.7 million in Q4 2025 and bottomed at $16.2 million in Q3 2022.
  • Average Operating Expenses over 5 years is $51.7 million, with a median of $34.1 million recorded in 2024.
  • Year-over-year, Operating Expenses rose 13.45% in 2022 and then surged 256.28% in 2025.
  • Viking Therapeutics' Operating Expenses stood at $20.3 million in 2022, then soared by 44.38% to $29.3 million in 2023, then surged by 57.89% to $46.2 million in 2024, then soared by 256.28% to $164.7 million in 2025, then dropped by 0.37% to $164.1 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $164.1 million, $164.7 million, and $98.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.